Business Context and Reporting Period
This Form 8-K is filed by XpresSpa Group, Inc. (trading symbol: XSPA) on January 9, 2022. The report covers events occurring on January 9 and January 10, 2022, including the announcement of preliminary financial expectations for the fourth quarter and full fiscal year 2021, and the execution of a significant acquisition agreement.
Key Financial Metrics and Transactions
The filing does not provide definitive revenue, profit, cash flow, or margin figures for the reported period, as these are preliminary and subject to change in the upcoming Form 10-K. However, it details the following transaction metrics:
- Acquisition Price: Approximately $6.5 million in aggregate purchase price for HyperPointe (gcg Connect, LLC).
- Initial Equity Consideration: 552,486 shares of common stock issued to HyperPointe equityholders, valued at $1.81 per share (30-day VWAP ended Dec 31, 2021).
- Potential Earnout: Up to $7.5 million in cash or stock contingent on performance targets over three years.
- Maximum Potential Equity Issuance: Up to an additional 4,143,647 shares under the earnout provision.
- Employment Inducement: Options granted to purchase up to 1,000,000 shares of common stock to Ezra Ernst.
Material Changes and Strategic Developments
The primary material change reported is the strategic acquisition of HyperPointe, a provider of digital health solutions, to be integrated into the Company's XpresTest subsidiary. This transaction represents a significant expansion of the Company's business model beyond its traditional spa services into digital health and testing. Additionally, the Company announced the appointment of Ezra Ernst, former CEO of HyperPointe, as the CEO of XpresTest, Inc.
Guidance, Outlook, and Risks
Guidance and Outlook: The Company issued a press release on January 10, 2022, containing preliminary expectations for Q4 and full-year 2021 results. These figures are not definitive and are subject to revision upon the filing of the Form 10-K in March 2022. The acquisition is expected to close in the first quarter of 2022, subject to customary closing conditions.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include the uncertainty of the earnout performance targets, the potential dilution from the issuance of up to 4.7 million additional shares (initial plus earnout), and the risk that actual results may differ materially from preliminary expectations. The earnout settlement may be forced into cash if the Company lacks sufficient authorized unissued shares.
Investor Verification Checklist
- Verify the definitive financial results for Q4 and FY 2021 when the Form 10-K is filed in March 2022.
- Confirm the closing date of the HyperPointe acquisition and any changes to the purchase price or earnout terms.
- Monitor the Company's authorized share count to assess the likelihood of cash settlement for the earnout versus stock issuance.
- Review the integration plan for HyperPointe into the XpresTest subsidiary and the impact on future revenue streams.
- Check for any updates regarding the employment inducement award granted to Ezra Ernst.